Sage Therapeutics has launched another round of layoffs as it deals with the fallout of abandoning a key pipeline drug for Alzheimer's and Parkinson's disease.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
